June 8, 2015 Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
June 2, 2015 Kite Pharma Presents Clinical Biomarker Results in Patients Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy at the 2015 ASCO Annual Meeting
May 29, 2015 Kite Pharma to Present Clinical Biomarkers From Patients Treated With Anti-CD19 Chimeric Antigen Receptor T Cell Therapy at the 2015 ASCO Annual Meeting
May 28, 2015 Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
May 7, 2015 Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone
May 5, 2015 Capricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT
April 30, 2015 Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
April 29, 2015 Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015
April 22, 2015 Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
April 21, 2015 Kite Pharma Commends Honors Conferred to Drs. Owen Witte and Steven A. Rosenberg at the 2015 American Association for Cancer Research (AACR) Annual Meeting
April 21, 2015 Arno Therapeutics to Present Promising Data from Phase I Trial of Onapristone at AACR Annual Meeting 2015
April 13, 2015 Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015
April 8, 2015 Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure
April 6, 2015 Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute
March 31, 2015 Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure
